Nucl Med Mol Imaging.  2023 Aug;57(4):209-211. 10.1007/s13139-023-00800-x.

Molecular Imaging in Recurrent Prostate Cancer Presented as a Mixed Small Neuroendocrine Tumor/Acinar Adenocarcinoma

• Al‑Ibraheem A
• Al‑Adhami D
• Abdlkadir A
• Al‑Hajaj N
• Ghanem R
• Abu‑Hijlih R
• Salah S

• KMID: 2545318
• DOI: http://doi.org/10.1007/s13139-023-00800-x

Abstract

Molecular imaging is an important tool for evaluating patients with prostate cancer, including those with hybrid histopathology. Although rare, mixed small neuroendocrine tumor/acinar adenocarcinoma exhibit aggressive behavior that necessitates optimal therapy. Molecular imaging has been implemented previously to assess radioligand therapy eligibility in such cases. Interestingly, the uptake of radiotracers targeting prostate-specific membrane antigen (PSMA) and somatostatin receptor may be reduced and can potentially lead to false negative readings in certain tumor types with hybrid features. Therefore, physicians should be aware of different kinds of disparities when assessing these tumor types with the aforementioned modalities.

Keyword

Neuroendocrine prostatic cancers; FDG; PSMA ; DOTATOC; Molecular imaging